Arvinas (ARVN) to Release Earnings on Tuesday

Arvinas (NASDAQ:ARVN - Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of ($1.07) per share and revenue of $62.79 million for the quarter. Parties that wish to register for the company's conference call can do so using this link.

Arvinas (NASDAQ:ARVN - Get Free Report) last posted its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same quarter in the previous year, the business earned ($2.53) earnings per share. On average, analysts expect Arvinas to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arvinas Stock Down 3.4 %

ARVN stock opened at $17.08 on Thursday. The business has a 50 day moving average price of $18.38 and a 200 day moving average price of $22.76. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of -6.16 and a beta of 1.88. Arvinas has a fifty-two week low of $16.07 and a fifty-two week high of $51.51.

Insider Activity

In other news, insider Ian Taylor sold 9,020 shares of the business's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $16.71, for a total value of $150,724.20. Following the transaction, the insider now owns 159,121 shares of the company's stock, valued at approximately $2,658,911.91. The trade was a 5.36 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO John G. Houston sold 31,338 shares of the business's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.72, for a total value of $523,971.36. Following the completion of the transaction, the chief executive officer now directly owns 1,157,480 shares in the company, valued at approximately $19,353,065.60. The trade was a 2.64 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 41,572 shares of company stock valued at $695,030. Company insiders own 5.23% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Oppenheimer boosted their target price on Arvinas from $40.00 to $45.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 12th. Stifel Nicolaus decreased their target price on Arvinas from $63.00 to $51.00 and set a "buy" rating for the company in a research note on Wednesday, February 12th. HC Wainwright reaffirmed a "buy" rating and set a $87.00 price target on shares of Arvinas in a research report on Wednesday, December 11th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arvinas in a research report on Friday, February 7th. Finally, BMO Capital Markets reaffirmed an "outperform" rating and set a $82.00 price target (down previously from $88.00) on shares of Arvinas in a research report on Wednesday, February 12th. Twelve analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $60.00.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.